IPI Legacy Liquidation Co

IPI Legacy Liquidation Co (IMPL) priced its initial public offering on Apr 23, 2021 at $15.00 per share, within its $14.00–$16.00 range, raising $80M, and listed on Nasdaq Global Market. At the IPO price its market capitalization was about $291.2M. Fenwick & West advised the company and Wilson Sonsini advised the underwriters.

IPI Legacy Liquidation Co is a late-stage pharmaceutical company developing therapies for diseases with high unmet needs, initially in the central nervous system. Its Precision Olfactory Delivery technology delivers drugs through the upper nasal cavity, and its candidates include TRUDHESA for acute migraine.

Status

IPO

Ticker

IMPL

Exchange

Nasdaq Global Market

Priced

Apr 23, 2021

IPO price

$15.00

Price range

$14.00–$16.00

Raised

$80M

Market cap at IPO price

$291.2M

First filed

Apr 2, 2021

Company counsel

Fenwick & West

Underwriters' counsel

Wilson Sonsini

Sector

Biotech & pharma

Country / state

WA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.